Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2015 Dec 30;15(4):608–617. doi: 10.1158/1535-7163.MCT-15-0719

Figure 5. Treatment with 1 inhibits transcription of proangiogenic and prometastatic factors in tumors.

Figure 5

Mice harboring U251 tumors were treated according to Schedule D to capture gene expression profile underlying the changes in tumor mass and MVD (n=8 per condition). We registered a significant downregulation of several important proangiogenic factors (A), including Angiopoietins 1 and 2 (ANGPT1, ANGPT2), overall tumor levels of their receptor mouse-Tie-2 (Tek), Neuroligin 1 (NLGN1) as well as Platelet-Derived Growth Factor-B (PDGFB). Interestingly, both mRNA expression (B) and serum protein levels of a human-VEGFA (C) were upregulated slightly in treated animals (n=8,6 for samples treated with vehicle and 1). We selected a panel of prometastatic factors and found that 1 inhibits mRNA expression in all tested transcripts except MMP2 (D). Error bars denote 95% CI.